Clinical Trials on Leukemia, B-Cell

Total 37925 results

AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
University of Pennsylvania
Children's Hospital of Philadelphia

Recruiting

CD22 Redirected Autologous T Cells for ALL

B Cell Lymphomas | B Cell Leukemias

United States
Shanghai Tong Ren Hospital
Gracell Biotechnology Ltd.

Unknown

CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

B-cell Lymphoma | B-cell Malignancy | B-Cell Acute Lymphoblastic Leukaemia

China
King's College Hospital NHS Trust

Completed

CLL Empirical Antibiotic Regimen (CLEAR)

Chronic Lymphocytic Leukaemia (CLL)

United Kingdom
Novartis Pharmaceuticals

Completed

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, Chronic

United States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
GlaxoSmithKline

Completed

HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

Leukaemia, Lymphocytic, Chronic
French Innovative Leukemia Organisation

Terminated

Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL (BOMP)

B-cell Chronic Lymphocytic Leukemia (B-CLL)

France
Genzyme, a Sanofi Company
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Completed

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

B-Cell Chronic Lymphocytic Leukemia (B-CLL)

United Kingdom, Belgium, France, United States, Czech Republic, Serbia
Athenex, Inc.

Recruiting

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (ANCHOR2)

B-cell Lymphoma | CLL/SLL | ALL, Childhood | DLBCL - Diffuse Large B Cell Lymphoma | B-cell Leukemia | NHL, Relapsed, Adult | ALL, Adult B Cell

United States
Steven E. Coutre
Bayer

Completed

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia (CLL) | Chronic Leukemia | B-cell Leukemia

United States
French Innovative Leukemia Organisation
Roche Pharma AG

Completed

Intensified Rituimab Prephase Before FCR in Untreated B-CLL

B-cell Chronic Lymphocytic Leukemia CLL

France
University Hospital, Caen
CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France

Completed

Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies (FLUDATEP)

Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Study on the Diagnosis and Management of CLL in Italy by GIMEMA

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type

Italy
Karolinska University Hospital
Schering Nordiska AB

Completed

Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia

B-CLL

Sweden
GlaxoSmithKline

Completed

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

Leukaemia, Lymphoblastic

Japan
Sidney Kimmel Comprehensive Cancer Center at Johns...
Amgen

Active, not recruiting

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma | Pre B-Cell Acute Lymphoblastic Leukaemia

United States
Nanfang Hospital of Southern Medical University

Recruiting

Induced-T Cell Like NK Cells for B Cell Malignancies

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | B Cell Leukemia | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Abbott
Genentech, Inc.

Completed

Assess the Oral Bioavailability of New ABT-263 Formulations

Chronic Lymphocytic Leukemia | Lymphomas | Leukemias

United States
Novartis Pharmaceuticals

Completed

Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

India, United Kingdom, Netherlands, Canada, Germany, Greece, Italy, Poland, Russian Federation, Spain, Taiwan, Thailand, United States, Brazil, Bulgaria, Mexico, Romania, Ukraine
Novartis Pharmaceuticals

Terminated

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (COMPLEMENT 1)

Leukaemia, Lymphocytic, Chronic

Spain, United States, Belgium, India, United Kingdom, Netherlands, Czechia, Germany, Greece, Italy, Russian Federation, Sweden, Canada, Ireland, Poland, France, Brazil
Gilead Sciences

Completed

Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland (RETRO-idel)

Chronic Lymphocytic Leukaemia

United Kingdom, Ireland
GlaxoSmithKline

Completed

Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients (BIFROST)

Leukaemia, Lymphocytic, Chronic

United States, United Kingdom
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALL

United States
GlaxoSmithKline

Completed

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

Leukaemia, Lymphocytic, Chronic

Australia, United States, New Zealand
GlaxoSmithKline

Completed

Phase IV Observational Study in Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic
Novartis Pharmaceuticals

Completed

Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

Leukaemia

Belgium, Austria, Czechia, France, Germany, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Ireland, Italy, Slovakia, Bulgaria, Singapore, Ukraine, Poland
AstraZeneca

Recruiting

Retention Rate of Acalabrutinib in a Non-interventional Setting (RETAIN)

Chronic Lymphocytic Leukaemia (CLL)

Germany
Gruppo Italiano Studio Linfomi

Completed

Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders

Chronic Lymphocytic Leukaemia

Italy
University Hospital, Brest

Recruiting

Chronic Lymphoid Leukaemia Observatory in Finistere Area, France (OFICE)

Chronic Lymphoid Leukaemia

France
Novartis Pharmaceuticals

Terminated

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG)

Leukaemia, Lymphocytic, Chronic

Belgium, Netherlands, United States, Argentina, Czechia, Denmark, France, Greece, Israel, Russian Federation, Sweden, Korea, Republic of, Australia, Brazil, Canada, Italy, Spain, Turkey, Hungary, Finland, Poland, Ukraine, Puerto Rico, Indi... and more
University Health Network, Toronto
Celgene

Terminated

Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) (Rev-CLL)

Chronic Lymphocytic Leukaemia

Canada
University of Liverpool
GlaxoSmithKline; Chugai Pharma USA; Napp Pharmaceuticals Limited

Unknown

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment (RIAltO)

Chronic Lymphocytic Leukaemia

United Kingdom
The Christie NHS Foundation Trust
Celgene Corporation; Leukemia Research Fund

Terminated

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial (RESPeCT)

Chronic Lymphocytic Leukaemia

United Kingdom
Uppsala University
Uppsala University Hospital; AFA Insurance

Completed

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

B-Cell Lymphoma | B-cell Leukemia

Sweden
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...

Unknown

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
Royal Marsden NHS Foundation Trust

Completed

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

Chronic Lymphocytic Leukaemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients

Elderly Patients | Small Lymphocytic Lymphoma | CLL | B-cell | Untreated B-CLL

Italy
Hebei Senlang Biotechnology Inc., Ltd.
The Second Hospital of Hebei Medical University

Unknown

CAR T Cells for Refractory B Cell Malignancy

B-Cell Leukemia | B-Cell Lymphoma

China
Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust; University Hospital Plymouth...

Unknown

Tissue Collection for Biomarkers Determining Resistance to Ibrutinib (CLARITY)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukaemia

United Kingdom
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukaemia (CLL) | Multiple Myeloma (MM) | B-Cell Non-Hodgkin Lymphoma (NHL)

France, Australia, Germany, Korea, Republic of, United Kingdom, Hungary, Poland, Singapore
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
University of Pennsylvania

Completed

Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)

B Cell Lymphoma | B Cell Leukemia

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

CD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-Cell

China
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...

United States
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China

Clinical Trials on Leukemia, B-Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations